MONOMORPHIC EPITHELIOTROPIC INTESTINAL T-CELL LYMPHOMA
Clinical trials for MONOMORPHIC EPITHELIOTROPIC INTESTINAL T-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new MONOMORPHIC EPITHELIOTROPIC INTESTINAL T-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for MONOMORPHIC EPITHELIOTROPIC INTESTINAL T-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo therapy hopes to boost remission in tough lymphoma
Disease control TerminatedThis study is for people with a rare type of blood cancer called peripheral T-cell lymphoma that hasn't been treated yet. It compares standard chemotherapy alone versus adding either duvelisib or CC-486 to the chemo. The goal is to see if these added drugs can improve the chance …
Matched conditions: MONOMORPHIC EPITHELIOTROPIC INTESTINAL T-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated May 26, 2026 11:33 UTC
-
New drug combo targets tough T-Cell lymphoma
Disease control TerminatedThis early-stage study tests whether combining two existing drugs, azacitidine and abatacept, can shrink tumors in people with T-cell lymphoma that has come back or not responded to prior therapy. About 20 adults will receive the drugs in 28-day cycles for up to 13 cycles. The go…
Matched conditions: MONOMORPHIC EPITHELIOTROPIC INTESTINAL T-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 13:55 UTC
-
Engineered donor cells take aim at Hard-to-Treat blood cancers
Disease control OngoingThis early-phase study tests a new type of CAR T-cell therapy made from donor cells (WU-CART-007) for people with CD7-positive blood cancers, including acute myeloid leukemia and T-cell lymphoma that have not responded to standard treatments. The therapy is designed to target and…
Matched conditions: MONOMORPHIC EPITHELIOTROPIC INTESTINAL T-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated May 19, 2026 11:47 UTC
-
Promising lymphoma combo study pulled before starting
Disease control TerminatedThis study was designed to see if adding tazemetostat to standard CHOP chemotherapy could improve outcomes for people with untreated peripheral T cell lymphoma. It was withdrawn before any participants enrolled, so no results are available. The goal was to increase the number of …
Matched conditions: MONOMORPHIC EPITHELIOTROPIC INTESTINAL T-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Eric Jacobsen, MD • Aim: Disease control
Last updated May 18, 2026 12:10 UTC